• 11/25/2025, Sophia Antipolis, France

    Median Technologies to showcase AI-powered Software as a Medical Device eyonis® LCS for lung cancer screening at the RSNA 2025 Annual Meeting

    Median Technologies will attend the Radiological Society of North America (RSNA) 2025 Annual Meeting in Chicago, Il, USA, from Nov 30-Dec. 4, 2025. Median iCRO and eyonis® teams will welcome interested parties at Booth #5438, AI Showcase, South Hall, Level 3, McCormick Place, from Nov 30 – Dec 3 (technical exhibits dates).
    Read more Download 20251125_PR_RSNA2025_EN.pdf
  • 11/13/2025, Sophia-Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of October 31, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of October 31, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20251113_PR_shares_votingrights_oct2025.pdf
  • 11/03/2025, Sophia Antipolis, France

    Median Technologies appoints Didric Cederholm to its Board of Directors

    Didric Cederholm is a Founding Partner and the Chief Investment Officer of Lion Point Capital, a global special situations investment fund. Prior to founding Lion Point Capital, Didric spent nearly eight years at Elliott Management and was previously a Principal at Eos Partners.
    Read more Download 20251103_PR_BoardAppointment_EN_final.pdf
  • 10/23/2025, Sophia Antipolis, France

    Median Technologies reports first-half 2025 financial results and provides key Q3 2025 business results

    Median Technologies today reported its consolidated financial results for the six month period ending June 30, 2025 and provided key business results (unaudited) for the third quarter of 2025.
    Read more Download 20251023_HY2025andQ3_EN_final.pdf
  • 10/21/2025, Sophia Antipolis, France

    Median Technologies receives €19 million from the European Investment Bank, corresponding to the first tranche under the 2025 loan facility

    Median Technologies announced today the receipt of a €19 million payment under the first tranche of the financial agreement executed with the European Investment Bank (EIB) on July 11, 2025, which has a total value of up to €37.5 million.
    Read more Download 20251021_EIBtranche_Drawdown_EN_final.pdf
  • 10/13/2025, Sophia Antipolis, France

    Median Technologies announces the availability of the preparatory documents for the Shareholders’ Ordinary and Extraordinary General Meeting on October 31, 2025

    The shareholders of Median Technologies are invited to participate in the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Friday, 31 October 2025, at 2:00 pm CET at PDGB, 174 avenue Victor Hugo – 75116 Paris.
    Read more Download 20251013_PR_OEGM_31october2025_EN.pdf
  • 10/06/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of September 30, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of September 30, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20251006_PR_shares_votingrights_Sep2025.pdf
  • 09/22/2025, Sophia Antipolis, France

    Median Technologies business update following successful financing

    Press release – For immediate release – 05:45 pm CEST Median Technologies business update following successful financing Cash runway extended until at least Q4 2026 and potentially well beyond eyonis® LCS commercial launch preparations underway in the U.S. eyonis® LCS subject to advanced negotiations for U.S. commercialization partners Reviews ongoing for market authorization of eyonis® LCS […]
    Read more Download 20250922_PR_Businessupdate_EN_clean.pdf
  • 09/08/2025, Sophia Antipolis, France

    H2 2025 Financial Communication Calendar

    Median Technologies, manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announces today its H2 2025 financial communication calendar.
    Read more Download 20250908_H2financialcommunicationschedule_Final-1.pdf
  • 09/04/2025, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of August 31, 2025

    Disclosure of total number of voting rights and number of shares in the capital as of August 31, 2025, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20250904_PR_shares_votingrights_August2025.pdf
    • 1 … 43